Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

Registered drugNo placebo

Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ribociclib
Sponsor:Institut Für Frauengesundheit GmbH

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Nucresiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Glucose tolerance impaired

Recruiting

Evaluation of controlled-ileal-release nicotinic acid tablets compared to placebo for treating people with prediabetes

Investigational

Evaluation of controlled-ileal-release nicotinic acid tablets compared to placebo for treating people with prediabetes

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Nicotinic acid
Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Contact Research Centre

Non-small cell lung cancer+5

Recruiting

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Ficerafusp alfa
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

Colitis microscopic

Recruiting

Study of SAR444336 in Adults with Microscopic Colitis Who Achieved Clinical Remission with Budesonide Treatment

Investigational

Study of SAR444336 in Adults with Microscopic Colitis Who Achieved Clinical Remission with Budesonide Treatment

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:SAR444336
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Registered drugNo placebo

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Fondazione GONO G.I.

Contact Research Centre

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Atrial fibrillation+1

Recruiting

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Flecainide Acetate
Sponsor:University Medical Center Hamburg-Eppendorf

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Potsdam

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for triple-negative, HER2-positive, and hormone receptor-positive variants. Research encompasses new combination therapies and targeted treatments.

Early-stage breast cancer interventions
HPV-positive oropharyngeal cancer treatments
Advanced treatment strategies

Multiple studies are evaluating novel drug combinations and personalized therapeutic approaches.

02 Dermatological Studies

Clinical research targeting various skin conditions, including atopic dermatitis and chronic skin disorders. Studies focus on both topical and systemic treatments.

Actinic keratosis treatments
Hidradenitis suppurativa therapy
Plaque psoriasis management

Investigations include both traditional and innovative therapeutic approaches for skin conditions.

03 Neurological Research

Studies focusing on multiple sclerosis treatment options, evaluating new medications and comparing their effectiveness to existing therapies.

Relapsing-remitting MS treatments
Novel therapeutic approaches
Disease modification strategies

Research aims to improve treatment outcomes and quality of life for patients with neurological conditions.

04 Cardiovascular Studies

Research focusing on cardiovascular disease management and innovative treatments for related conditions, including studies on lipid management.

Lipoprotein management
Cholesterol reduction therapies
Cardiovascular risk prevention

Trials aim to reduce major cardiovascular events and improve patient outcomes.

Back to Germany All countries